How ESE is Funded
The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2017 financial year.
ESE is funded through a number of industry and non-industry sources;
- Membership – individual
- Membership – Corporate – See all our Corporate members
- Revenue generated by ESE owned journal ‘European Journal of Endocrinology’
- Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education
- The list of all industry and non-industry revenue sources in 2017 are listed below:
- A.I.C. Asti Incentives & Congressi Srl
- Aegerion Pharmaceuticals
- AmCad BioMed
- Chiasma
- Clinical Endocrinology Trust
- Eli Lilly
- Elsevier Mason
- EndoBridge 2017
- HRA Pharma
- Ipsen
- Novartis
- Novo Nordisk
- Pfizer
- Pheonix
- Sandoz
- Shire
- Siemens
- Strongbridge Biopharma (formerly Cortendo)
- ThermoFisher
- Wisepress
- Of the revenue into ESE in the 2017 accounts 31% was provided by industry
- The highest contribution from a single company represented 20.5% of the industry revenue and 6.4% of ESE revenue overall.